Login

Switch On Your HIV Smarts.

Author Archives: Liz Highleyman

Hormone levels not affected by PrEP in trans women

Hormone levels not affected by PrEP in trans women

, by Liz Highleyman

Using PrEP for HIV prevention does not lower levels of feminizing hormones, and hormones only slightly reduce tenofovir levels according to new research. Read More

PrEP scales up, HIV incidence declines

PrEP scales up, HIV incidence declines

, by Liz Highleyman

We’re starting to see the effects of PrEP on population-level measures of HIV incidence, but progress is uneven. Read More

PrEP use since 2012 is up, but uptake falls short of need

PrEP use since 2012 is up, but uptake falls short of need

, by Liz Highleyman

1.45 million Americans may be at substantial risk for HIV infection, but only 8% are taking PrEP. Women, people of color, and southern regions are underrepresented. Read More

CROI 2018: A roundup of the most exciting PrEP news & research

CROI 2018: A roundup of the most exciting PrEP news & research

, by Liz Highleyman

Liz Highleyman summarizes the PrEP and HIV prevention research presented recently at the domestic HIV conference, CROI, including a new possible PrEP drug, real world PrEP effectiveness, and more. Read More

HIV remission: more clues, but still many questions

HIV remission: more clues, but still many questions

, by Liz Highleyman

Very early HIV treatment does not cure HIV, but can lead to HIV remission in some people, new studies presented at IAS 2017 show. Read More